Tannock I F, Browman G
J Clin Oncol. 1986 Jul;4(7):1121-6. doi: 10.1200/JCO.1986.4.7.1121.
Numerous single-arm studies have shown that chemotherapy may produce a high rate of response and rapid shrinkage of tumor when used before radiation and/or surgery in patients with squamous-cell carcinoma of the head and neck. Despite this high rate of tumor response, randomized controlled trials do not indicate any consistent improvement in survival for patients receiving chemotherapy as compared with patients receiving local treatment alone. This population of patients often has poor performance status, and chemotherapy invariable adds some toxicity. Also, studies in animals suggest that some types of chemotherapy given before local radiation or surgery might increase the probability of distant metastases. Apart from pilot studies of feasibility, all future trials of chemotherapy should involve a randomized comparison with a group of patients receiving radiation and/or surgery alone. At present, chemotherapy has no place in the routine management of primary head and neck cancer.
众多单臂研究表明,对于头颈部鳞状细胞癌患者,在放疗和/或手术前使用化疗可能会产生较高的缓解率,并使肿瘤迅速缩小。尽管肿瘤缓解率较高,但随机对照试验并未表明接受化疗的患者与仅接受局部治疗的患者相比,在生存率方面有任何一致的改善。这类患者通常身体状况较差,化疗不可避免地会增加一些毒性。此外,动物研究表明,在局部放疗或手术前给予某些类型的化疗可能会增加远处转移的可能性。除了可行性的初步研究外,未来所有化疗试验都应与一组仅接受放疗和/或手术的患者进行随机对照比较。目前,化疗在原发性头颈部癌的常规治疗中没有地位。